Agrylin (anagrelide) is the first drug specifically approved for patients with essential thrombocythemia

January 1998

Agrylin (anagrelide) is the first drug specifically approved for patients with essential thrombocythemia.

These patients have ELEVATED platelet counts...about six times higher than usual.

Too many platelets increase the risk of thrombosis...leading to heart attack and stroke.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

New designer estrogens
Cholesterol Pravachol (pravastatin) is approved to prevent a first heart attack
Cholesterol How do "stain" doses compare?
Interactions Significant interaction between Buspar (buspirone) and erythromycin or itraconazole
Ophthalmology New eye drop for glaucoma, Alphagan (brimonidine)
Ophthalmology Patanol (olopatadine), a new prescription antihistamine eye drop
Seroquel (quetiapine) just hit the market
Zomig (zolmitriptan) for migraines
Diabetes Stop making Iletin I (beef/pork) insulin this year
Diabetes Monitor Long-Term blood sugar control at home
Hematology & Oncology The first monoclonal antibody for cancer
Cardiology Plavix (clopidogrel) to prevent recurrent heart attacks or ischemic strokes
Cardiology Agrylin (anagrelide) is the first drug specifically approved for patients with essential thrombocythemia
Cardiology Eminase (anistreplase) is a new thrombolytic
Glaxo will soon introduce two new Dry Powder inhalers
Hair Loss Two new treatments for hair loss
Oral Health New prescription drug for aphthous ulcers or canker sores
Milk thistle to prevent liver toxicity
Practice First pediatric ibuprofen products